Activity: Membership › Membership of committee › Research
Description
NICE Clinical Expert on Rapid Technology Review Committee 2017-20: Impact – successful appeal of NICE initial decision not to fund the first-in-class systemic photoprotective drug (Afamelanotide) for a photosensitivity disorder (erythropoietic protoporphyria, EPP)
Period
2017 → 2020
Held at
The National Institute for Health & Care Excellence, United Kingdom
Degree of Recognition
National
Research Beacons, Institutes and Platforms
Lydia Becker Institute
Manchester Institute for Collaborative Research on Ageing